Lenacapavir: A Game-Changer in HIV Prevention and Treatment
TL;DR Summary
Lenacapavir, a new drug hailed as the 2024 Breakthrough of the Year by Science, shows promise in virtually eliminating new HIV infections through sex, with clinical trials demonstrating up to 100% efficacy. Administered biannually, it offers a significant alternative to daily oral PrEP, which faces adherence challenges. While lenacapavir's high cost poses accessibility issues, its potential to transform HIV prevention, especially in high-burden regions like sub-Saharan Africa, is significant. Efforts are underway to make it widely available by 2025.
- This drug is the 'breakthrough of the year' — and it could mean the end of the HIV epidemic NPR
- Gilead to test once-a-year HIV prevention shot STAT
- Who’s Going to Get Lenacapavir for HIV Prevention? NEJM Journal Watch Medical Blogs
- Science’s 2024 Breakthrough of the Year: Opening the door to a new era of HIV prevention Science
- Lenacapavir treats and prevents HIV, it does not cure infection | Fact check USA TODAY
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
5 min
vs 6 min read
Condensed
93%
1,170 → 79 words
Want the full story? Read the original article
Read on NPR